Publications (6)4.82 Total impact
-
Article: Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo.
[show abstract] [hide abstract]
ABSTRACT: Curcumin, the main compound of spice turmeric, is one of the natural products that has been shown to possess effective anti-cancer properties. However, the absorption efficacy of curcumin is too low to make dramatic results in therapy. Therefore, we based the main aim of this study on improving the bioavailability of curcumin taking advantage of dendrosome nanoparticles; and subsequently evaluating in vitro and in vivo anti-tumor properties of dendrosomal curcumin. In vitro studies were carried out utilizing A431 and WEHI-164 cell lines and mouse embryonic normal fibroblasts. Our data revealed that dendrosomal curcumin not only exhibits a much higher bioavailability than void curcumin (P<0.05) but also inhibits the proliferation of cancer cells (P<0.01) in a time- and dose-dependent manner that could be ascribed to the induction of apoptosis. However, dendrosome did not indicate any toxic effect on different types of cell lines. For in vivo studies, BALB/c tumor-bearing mice were treated with dendrosomal curcumin, void curcumin, dendrosome and PBS. The results indicated that dendrosomal curcumin reduces significantly the tumor size in comparison with void curcumin and control samples (P<0.05). Furthermore, in animals treated with dendrosomal curcumin a longer survival was observed (P<0.01). We also found that the mice treated with dendrosomal curcumin, showed a significant increase in splenocyte proliferation and IFN-γ production as well as a significant decrease in IL-4 production. This can be a proof of anti-tumor immunity caused by dendrosomal curcumin. The findings demonstrate that dendrosomal curcumin offers a great potential to be a promising anti-cancer therapeutic agent.International immunopharmacology 12/2011; 12(1):226-34. · 2.21 Impact Factor -
Article: A novel mutation (4040-4045 nt. delA) in exon 14 of the factor VIII gene causing severe hemophilia A.
[show abstract] [hide abstract]
ABSTRACT: Hemophilia A is an X-linked congenital bleeding disorder caused by Factor VIII deficiency. Different mutations including point mutations, deletions, insertions and inversions have been reported in the FVIII gene, which cause hemophilia A. In the current study, with the use of conformational sensitive gel electrophoresis (CSGE) analysis, we report a novel 1-nt deletion in the A6 sequence at codons 1328-1330 (4040-4045 nt delA) occurring in exon 14 of the FVIII gene in a seven-year-old Iranian boy with severe hemophilia A. This mutation that causes frameshift and premature stop-codon at 1331 has not previously been reported in the F8 Hemophilia A Mutation, Structure, Test and Resource Site (HAMSTeRS) database.Indian Journal of Human Genetics 09/2011; 17(3):232-4. -
Article: Application of quartz crystal nanobalance and principal component analysis for detection and determination of nickel in solution.
[show abstract] [hide abstract]
ABSTRACT: Quartz crystal nanobalance (QCN) sensors are considered as powerful mass sensitive sensors to determine materials in the sub-nanogram level. In the first part of this study, a single piezoelectric QCN modified with polypyrrole (PPy) has been tested for detection and determination of nickel ions in the solution at room temperature. The developed method was successfully applied for detection of total nickel in samples taken from several hot springs located at the Northwest of Iran. The frequency shifts were linear with respect to the concentration of nickel in solution. Using this method, nickel can be measured in the range of 3-20 mg L(-1). A lower limit of detection of 0.79 mg L(-1) and a sensitivity factor of 4.429 Hz/mg L(-1) were obtained. Some possible interference such as heavy metal ions (lead, mercury, and cadmium) was checked. No major interference was observed with the performance of the sensor except for mercury. To evaluate the ability of the PPy-modified QCN in discriminating between nickel ions and interfering mercury ions, a principal component analysis (PCA) was carried out. PCA was utilized to process the frequency response data of the single piezoelectric crystal at different times, considering different adsorption-desorption dynamics of nickel and interfering mercury ions on electrode. Using PCA, it was found that about 97.90% of the data variance could still be explained by two principal components (PC1 and PC2). The score plot of the data for the first two PCs showed that the PPy-modified QCN yields favorable identification and quantification performances for nickel ions. The accuracy of method for hot spring samples was evaluated and RSD of 4.10% was obtained.Journal of Environmental Science and Health Part A Toxic/Hazardous Substances & Environmental Engineering 01/2010; 45(9):1119-25. -
Article: β-Thalassemia Mutations in the Iranian Kurdish Population of Kurdistan and West Azerbaijan Provinces
[show abstract] [hide abstract]
ABSTRACT: The aim of this study was to investigate the prevalence and spectrum of β-thalassemia (β-thal) mutations in the population of Sunni Muslim Kurds in western Iran and to set up a prenatal diagnostic laboratory. Sixty unrelated Kurdish β-thal patients identified in hematology clinics from different cities were studied. The mutations in 120 chromosomes were studied by polymerase chain reaction–amplification refractory mutation system and direct sequencing methods. We found fifteen β-thal mutations, and IVS-II-1 (G>A) was the most frequent, comprising 35% of all mutations. Other common mutations were frameshift codons 8/9 (+G) 15.7%, IVS-I-1 (G>A) 8%, FSC 5 (–CT) 6.7%, FSC 8 (–AA) 6.7%, and IVS-I-110 (G>A) 6%. This is the first comprehensive study in this region and could provide a reference for prenatal testing and genetic counseling in this population.07/2009; 33(2):109-114. -
Article: Is the frameshift codons 8/9 (+G) [FSC 8/9 (+G)] beta-thalassemia mutation, detected by the polymerase chain reaction-amplification refractory mutation system, really FSC 8/9 (+G)?
[show abstract] [hide abstract]
ABSTRACT: There are several polymerase chain reaction (PCR)-based approaches for the analysis of known mutations. The PCR-amplification refractory mutation system (PCR-ARMS) is one of the best known and frequently used for the detection of beta-thalassemia (beta-thal) mutations. However, there is an important point to be considered when searching for the frameshift codon (FSC) 8 (-AA) and FSC 8/9 (+G) mutations. Whereas the primer is specific for the FSC 8 mutation only, the primer for the FSC 8/9 mutation does not discriminate between the FSC 8/9 and FSC 8 mutations. Thus, the high number of FSC8/9 mutations reported in countries like India, Pakistan and some regions of Iran may be due to the use of the FSC 8/9 primer, without taking the FSC 8 mutation into account. It is thus advisable to test for FSC 8 before the FSC 8/9 mutation whenever PCR-ARMS is the method of investigation for these two mutations.Hemoglobin 02/2009; 33(3):279-82. · 1.30 Impact Factor -
Article: beta-Thalassemia mutations in the Iranian Kurdish population of Kurdistan and West Azerbaijan provinces.
[show abstract] [hide abstract]
ABSTRACT: The aim of this study was to investigate the prevalence and spectrum of beta-thalassemia (beta-thal) mutations in the population of Sunni Muslim Kurds in western Iran and to set up a prenatal diagnostic laboratory. Sixty unrelated Kurdish beta-thal patients identified in hematology clinics from different cities were studied. The mutations in 120 chromosomes were studied by polymerase chain reaction-amplification refractory mutation system and direct sequencing methods. We found fifteen beta-thal mutations, and IVS-II-1 (G>A) was the most frequent, comprising 35% of all mutations. Other common mutations were frameshift codons 8/9 (+G) 15.7%, IVS-I-1 (G>A) 8%, FSC 5 (-CT) 6.7%, FSC 8 (-AA) 6.7%, and IVS-I-110 (G>A) 6%. This is the first comprehensive study in this region and could provide a reference for prenatal testing and genetic counseling in this population.Hemoglobin 01/2009; 33(2):109-14. · 1.30 Impact Factor
